IndraLab

Statements

reach
"XREF_BIBR Cl - channel blockers such as mefenamic acid, flufenamic acid, benzoic acid, etc, can inhibit the NLRP3 activation."
33814921
reach
"Mefenamic acid which belongs to fenamate group inhibits the NLRP3 inflammasome by inhibiting efflux of chloride ions and influx of calcium ions through blocking VRAC and TRPM2 respectively."
35438288
reach
"Flufenamic acid and mefenamic acid inhibit NLRP3 inflammasome activation through the suppression of chloride efflux."
29021150
reach
"A few NLRP3 inflammasome inhibitors, including sulforaphane, isoliquiritigenin, beta-hydroxybutyrate (BHB), flufenamic acid, mefenamic acid, 3,4-methylenedioxy-beta-nitrostyrene (MNS), parthenolide, BAY 11-7082, INF39, and MCC950, have been developed, but there is no evidence showing that these compounds can specifically and directly inhibit NLRP3 itself."
29021150
reach
"Various Cl - channel inhibitors, including 4,4 '-diisothiocyano-2,2 ' stilbene-disulfonic acid (DIDS), 5-nitro-(3-phenylpropylamino) benzoic acid (NPPB), flufenamic acid, mefenamic acid, and indanyloxyacetic acid 94 (IAA94), block the NLRP3 inflammasome but can not block the NLRC4 or AIM2 inflammasomes."
33603747
reach
"Different NLRP3 inflammasome inhibitors, including sulforaphane, β-hydroxybutyrate, glyburide, flufenamic acid, mefenamic acid, parthenolide, BAY 11-7082, INF39, and MCC950 have been developed, but there is no evidence demonstrating that these compounds directly and specifically target NLRP3 itself (212)."
30619282
reach
"Studies have shown that, unlike other NSAIDs, fenamates (mefenamic acid, flufenamic acid) selectively inhibit the NLRP3 inflammasome and IL-1beta release via inhibiting the membrane volume regulated anion (Cl -) channel (VRAC), independent of its cyclooxygenase-1 (COX-1) mediated anti-inflammatory activity."
32574259